Pharmaceutical Companies
-
Solid Biosciences receives FDA rare pediatric disease designation for Friedreich’s Ataxia Gene Therapy SGT-212
The therapy delivers the full-length human frataxin gene using a dual-administration approach that combines direct intradentate nucleus (IDN) injection with intravenous (IV) infusion.
-
Novartis gains FDA approval for Itvisma gene therapy to treat spinal muscular atrophy
Itvisma works by delivering a functional copy of the survival motor neuron 1 (SMN1) gene through a single, fixed-dose intrathecal injection.
-
SK Biopharmaceuticals expands oncology pipeline with US radiopharmaceutical deal.
WT-7695, a preclinical radiopharmaceutical targeting carbonic anhydrase IX (CA9), was developed in collaboration with the University of Wisconsin-Madison, and SK now holds exclusive worldwide rights to develop, manufacture, and market the drug.
-
Daikin begins construction of advanced manufacturing facility in Jeddah to boost HVAC production
The project, supported by Tariq Almutlaq, Chairman of Daikin Saudi Arabia and a longtime partner, aims to localize production for key HVAC components, including chillers and hydronic heat pumps designed for sophisticated cooling requirements.
-
Genmab halts phase 1/2 trial for oncology candidate GEN1160 amid broader strategic review
GEN1160 now joins GEN1107 on Genmab’s list of discontinued assets from the April 2024 ProfoundBio acquisition.
-
Moderna axes three clinical-stage mRNA candidates to focus R&D on oncology
A company spokesperson explained that Moderna has “prioritized our pipeline and R&D investments as part of our broader cost efficiency efforts,” though the company provided no additional details about the specific discontinuations.
-
Merck KGaA enters USD3B AI drug discovery partnership with Valo Health to target Parkinson’s disease
Through this partnership, Merck gains access to Valo’s advanced AI-powered human causal biology and discovery platforms, which the drugmaker will use to identify new disease targets and develop preclinical compounds.
-
Syntegon reports 19% sales growth in Q3 2025 driven by pharma innovation
The company’s Pharma business unit led the strong performance, delivering sales growth of 32%, including 20% organic growth.
-
AstraZeneca commits USD2B to expand Maryland manufacturing operations
The new facility will produce molecules for medical trials. These expansions will create 200 additional jobs in Frederick and 100 more in Gaithersburg.